Latest Breaking News On - Intestinal polypeptide - Page 1 : comparemela.com

Search jobs 30-Dec-2020 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study 30.12.2020 / 07:00 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure Geneva, Switzerland and Radnor, Pa, USA, December 30, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ( Relief or the Company ) and NeuroRx, Inc. today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI(TM) (previously RLF-100 TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. Top

United statesEli lillyAnne hennecke brittney sojevaJonathanc javittDavid schullRaghuram ram selvarajuRobert besthofJonathan javittBrian korbRusso partnersHoldings ag keySpain divisionMc servicesSwiss exchangeStony brook universityBig rock partners acquisition corp